GenScript and T-MAXIMUM partner for CAR-T cell therapy development
2023-08-10
细胞疗法免疫疗法基因疗法
Preview
来源: Pharmaceutical Technology
The partnership will develop CAR-T cell therapy by leveraging GenScript’s CRISPR nucleic acid re-agents. Credit: Design_Cells / Shutterstock.com.
Preview
来源: Pharmaceutical Technology
Genscript Biotech has formed a strategic collaboration agreement with T-MAXIMUM Biotech to develop CAR-T cell therapy.
Leveraging GenScript’s CRISPR nucleic acid re-agents, the partnership will focus on developing T-MAXIMUM’s CAR-T cell therapy.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - CD19/BCMA Targeted CAR T-Cells GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - CAR-T Cell Multiple Myeloma GlobalData
View allCompanies IntelligenceGenscript Biotech CorpRAMP Inc.GenScript Corp.View all
GenScript research and development (R&D) and manufacturing vice-president Dr Li Hong stated: “Our R&D-to-GMP-level sgRNA will support their UCAR-T products for solid tumours. While CAR-T cell therapies have made remarkable strides in haematological tumours, addressing the unmet need for solid tumours remains crucial.”
T-MAXIMUM will receive a number of CRISPR re-agents from GenScript. These will support the development of T-MAXIMUM’s universal CAR-T products from discovery to commercialisation.
GenScript’s partnership with T-MAXIMUM will drive the latter’s strategic development plan, advancing products into Phase II clinical research and enabling market delivery up to 2027.
T-MAXIMUM is currently focused on the development of its universal CAR-T cell therapy product, MT027, to treat recurrent high-grade gliomas.
T-MAXIMUM CEO Dr Shang Xiaoyun stated: “Gene-editing reagents are crucial raw materials for the quality and efficacy of our products. We are confident that this collaboration will accelerate the regulatory processes in China and the US, expediting T-MAXIMUM’s first product pipeline to benefit patients in need as soon as possible.”
With business operations in more than 100 countries and regions across the world, GenScript offers life-science R&D and manufacturing services.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
来源: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。